YPrime Research Shows 74% Fewer Localization Errors in eCOA Migration with AI-Enabled Workflows

MALVERN, Pa., Nov. 18, 2025 (GLOBE NEWSWIRE) — YPrime, a proven leader in clinical trial technology, today released new findings showing that applying AI within the eCOA localization process delivers measurable quality gains–achieving 74% fewer migration errors, two-thirds faster review cycles, and greater global trial inclusivity. The research, “Garbage In, Garbage Out: Can AI Reduce […]

FINAL NOTICE: Kaskela Law LLC Announces Investigation into Proposed $59.00 Per Share Buyout of Heidrick & Struggles (NASDAQ: HSII) Stockholders and Encourages Investors to Contact the Firm to Protect Their Investment

(NASDAQ:HSII), PHILADELPHIA , Nov. 18, 2025 (GLOBE NEWSWIRE) — Kaskela Law LLC announces that it is investigating the fairness of the recently announced proposed buyout of Heidrick & Struggles International, Inc. (NASDAQ: HSII) (“Heidrick”) stockholders to determine whether the buyout price undervalues the company's shares. Click here for additional information about your legal rights and options: https://kaskelalaw.com/case/heidrick-struggles/

FINAL NOTICE: Kaskela Law LLC Announces Investigation into Proposed $59.00 Per Share Buyout of Heidrick & Struggles (NASDAQ: HSII) Stockholders and Encourages Investors to Contact the Firm to Protect Their Investment

(NASDAQ:HSII), PHILADELPHIA , Nov. 18, 2025 (GLOBE NEWSWIRE) — Kaskela Law LLC announces that it is investigating the fairness of the recently announced proposed buyout of Heidrick & Struggles International, Inc. (NASDAQ: HSII) (“Heidrick”) stockholders to determine whether the buyout price undervalues the company's shares. Click here for additional information about your legal rights and options: https://kaskelalaw.com/case/heidrick-struggles/

Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the Company will be featured in a key opinion leader (KOL) webinar, “Redefining SoC in Complicated Staph. aureus Bacteremia to

SHAREHOLDER ALERT: Kaskela Law LLC Announces Probe into Fairness of Electronic Arts Inc. (EA) Proposed $210.00 Per Share Buyout and Encourages Investors to Contact the Firm

(NASDAQ:EA), PHILADELPHIA , Nov. 18, 2025 (GLOBE NEWSWIRE) — Kaskela Law LLC announces that it is investigating the recently announced proposed buyout of Electronic Arts Inc. (NASDAQ: EA) (“EA” or the “Company”) shareholders to determine whether the buyout agreement is fair to the Company's investors. Click here for additional information about your legal rights and options: https://kaskelalaw.com/case/electronic-arts/

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO(R) for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

(NasdaqGM:ESPR),(TSX:HLS), ANN ARBOR, Mich., Nov. 18, 2025 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced that HLS Therapeutics Inc. (TSX: HLS), the Company's partner in Canada for the development and commercialization of NILEMDO(R) (bempedoic acid) and NEXLIZET(R) (bempedoic acid and ezetimibe), has received approval from Health Canada to market NILEMDO for the reduction of LDL-Cholesterol

Harrow Announces Closing of Acquisition of Melt Pharmaceuticals

(NasdaqGM:HROW), NASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) — Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the acquisition of Melt Pharmaceuticals, Inc. (Melt), a clinical-stage pharmaceutical company pioneering non-opioid, non-IV therapies for sedation for medical procedures in the hospital, outpatient, and in-office

Ultralife Corporation Reports Third Quarter Results

(NasdaqGM:ULBI), NEWARK, N.Y., Nov. 18, 2025 (GLOBE NEWSWIRE) — Ultralife Corporation (NASDAQ: ULBI) reported operating results for the third quarter ended September 30, 2025 with the following results: Sales of $43.4 million increased 21.5% from $35.7 million for the third quarter of 2024; excluding Electrochem, sales of $36.6 million increased 2.5% Gross profit of $9.6

BellRing Brands Reports Results for the Fourth Quarter and Fiscal Year 2025; Provides Fiscal Year 2026 Outlook and Updates Long-Term Financial Algorithm

(NYSE:BRBR), ST. LOUIS, Nov. 18, 2025 (GLOBE NEWSWIRE) — BellRing Brands, Inc. (NYSE:BRBR) (“BellRing”), a holding company operating in the global convenient nutrition category, today reported results for the fourth fiscal quarter and fiscal year ended September 30, 2025, provided its 2026 outlook and updated its long-term financial algorithm. Fourth Quarter and Fiscal Year 2025

REE Automotive and Mitsubishi Fuso Truck and Bus Corporation Sign MOU for Software-Defined Vehicle Technology

(NASDAQ:REE), Mitsubishi Fuso is collaborating with REE as part of an acceleration strategy to shift into software-defined trucks that are smarter, safer, and upgradable over-the-air Mitsubishi Fuso is evaluating REE's SDV and x-by-wire technologies for REE to serve as a potential supplier of a future vehicle platform The joint project has commenced and REE has

Scroll to Top